---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-060455"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:55:22.590887+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kodiak Sciences Q1 net loss $43M, cash $245.9M; advances tarcocimab and KSI-101 trials

## Summary
- Net loss of $43.0M ($0.82 per share) vs $70.8M ($1.35) in Q1 2023; includes $18.4M stock-based compensation.
- Cash and equivalents $245.9M; company expects runway into 2026.
- R&D expenses $29.9M, down from $56.5M YoY due to reduced tarcocimab clinical activities.
- GLOW2 Phase 3 diabetic retinopathy study actively enrolling; DAYBREAK wet AMD study activation targeted mid-2024.
- Phase 1b APEX study of KSI-101 (anti-IL-6/VEGF-trap) in macular edema expected to start enrollment in June 2024.

## SEC filing metadata
- accession: 0000950170-24-060455
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017024060455/0000950170-24-060455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017024060455/kod-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-060455
- JSON: https://secwatch.observer/filing/0000950170-24-060455.json
- Plain text: https://secwatch.observer/filing/0000950170-24-060455.txt

## Key facts
- Earnings Releases
  Kodiak Sciences Inc. reported the quarter ended March 31, 2024 results: net income $43.0 million, or $0.82 per share on both a basic and diluted basis, EPS $0.82 per share on both a basic and diluted basis.
  - Period: the quarter ended March 31, 2024
  - Net income: $43.0 million, or $0.82 per share on both a basic and diluted basis
  - EPS: $0.82 per share on both a basic and diluted basis
  - Result: reported results
  source text: Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468748/000095017024060455/0000950170-24-060455-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.